445 related articles for article (PubMed ID: 16181985)
1. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
[TBL] [Abstract][Full Text] [Related]
2. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel.
Lev EI; Patel RT; Guthikonda S; Lopez D; Bray PF; Kleiman NS
Thromb Res; 2007; 119(3):355-60. PubMed ID: 16581111
[TBL] [Abstract][Full Text] [Related]
4. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
[TBL] [Abstract][Full Text] [Related]
5. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
[TBL] [Abstract][Full Text] [Related]
6. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
[TBL] [Abstract][Full Text] [Related]
7. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
Rudez G; Bouman HJ; van Werkum JW; Leebeek FW; Kruit A; Ruven HJ; ten Berg JM; de Maat MP; Hackeng CM
Circ Cardiovasc Genet; 2009 Oct; 2(5):515-21. PubMed ID: 20031628
[TBL] [Abstract][Full Text] [Related]
8. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
9. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Am J Cardiol; 2005 Oct; 96(8):1095-9. PubMed ID: 16214444
[TBL] [Abstract][Full Text] [Related]
10. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
12. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
[TBL] [Abstract][Full Text] [Related]
13. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
Gurbel PA; Cummings CC; Bell CR; Alford AB; Meister AF; Serebruany VL;
Am Heart J; 2003 Feb; 145(2):239-47. PubMed ID: 12595840
[TBL] [Abstract][Full Text] [Related]
14. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.
Smith SM; Judge HM; Peters G; Armstrong M; Dupont A; Gaussem P; Storey RF
Platelets; 2005 Sep; 16(6):340-5. PubMed ID: 16194864
[TBL] [Abstract][Full Text] [Related]
15. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Diehl P; Olivier C; Halscheid C; Helbing T; Bode C; Moser M
Basic Res Cardiol; 2010 May; 105(3):379-87. PubMed ID: 19943165
[TBL] [Abstract][Full Text] [Related]
16. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
Smith SM; Judge HM; Peters G; Armstrong M; Fontana P; Gaussem P; Daly ME; Storey RF
Platelets; 2006 Jun; 17(4):250-8. PubMed ID: 16769602
[TBL] [Abstract][Full Text] [Related]
17. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.
Angiolillo DJ; Fernández-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Bañuelos C; Hernández-Antolín R; Escaned J; Moreno R; Alfonso F; Macaya C
Eur Heart J; 2004 Nov; 25(21):1903-10. PubMed ID: 15522469
[TBL] [Abstract][Full Text] [Related]
18. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
[TBL] [Abstract][Full Text] [Related]
19. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Guthikonda S; Alviar CL; Vaduganathan M; Arikan M; Tellez A; DeLao T; Granada JF; Dong JF; Kleiman NS; Lev EI
J Am Coll Cardiol; 2008 Aug; 52(9):743-9. PubMed ID: 18718422
[TBL] [Abstract][Full Text] [Related]
20. Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes.
Spiewak M; Małek ŁA; Kostrzewa G; Kisiel B; Serafin A; Filipiak KJ; Płoski R; Opolski G
Kardiol Pol; 2009 Aug; 67(8):827-34. PubMed ID: 19784880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
